0LIF.LSE Ultragenyx Pharmaceutical Inc.
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Is 0LIF.LSE undervalued?
Graham numberThe Graham number of Ultragenyx Pharmaceutical Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Ultragenyx Pharmaceutical Inc. fundamental analysis
No fundamental analysis for Ultragenyx Pharmaceutical Inc. yet.
Ultragenyx Pharmaceutical Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced …
Full company profileFinancial statements of Ultragenyx Pharmaceutical Inc. are not available yet.
Ultragenyx Pharmaceutical Inc. dividends
Ultragenyx Pharmaceutical Inc. has not paid dividends in the last 4 fiscal years.
Who owns Ultragenyx Pharmaceutical Inc.
- Insiders 3.43%
- Institutions 96.57%
- Public & others 0.00%
- Free float 74.1M
Ultragenyx Pharmaceutical Inc. company profile
- Company name
- Ultragenyx Pharmaceutical Inc.
- Ticker
- 0LIF.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,371
- Fiscal year end
- December
- Address
- 60 Leveroni Court, Novato, CA, United States, 94949
- Phone
- 415 483 8800
- Website
- ultragenyx.com
About Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701, an adeno-associated AAV9 gene therapy which is in Phase 2 clinical trial for the treatment of Wilson liver disease. The company has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Regeneron; and Abeona. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
Ultragenyx Pharmaceutical Inc. management
10- Dr. Emil D. Kakkis M.D., Ph.D.Founder, President, CEO & Director · born 1960
- Mr. Howard HornExecutive VP of Corporate Strategy & CFO · born 1979
- Ms. Karah Herdman Parschauer J.D.Chief Legal Officer & Executive VP of Corporate Affairs · born 1978
- Mr. Erik Harris M.B.A.Executive VP & Chief Commercial Officer · born 1970
- Dr. Eric Crombez M.D.Chief Medical Officer & Executive VP · born 1973
- Mr. Theodore A. HuizengaSenior VP, Corporate Controller & Principal Accounting Officer · born 1971
- Mr. Ernie W. MeyerChief Human Resources Officer & Executive VP · born 1965
- Mr. Vimal SrivastavaSenior Vice President of Business Development & Alliance Management · born 1965
- Mr. Dennis Karl HuangChief Technical Operations Officer and Executive VP of Gene Therapy Operations
- Mr. John Richard Pinion IIChief Quality Operations Officer & Executive VP of Translational Sciences · born 1966